Genetic Analysis AS (FRA:8V8) Marketable Securities: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8V8 Genetic Analysis AS FRA:8V8
39 GF Score
Price €0.02
GF Value €0.04
! 3 Warning Signs
View Full Analysis

What is Genetic Analysis AS Marketable Securities?

Genetic Analysis AS FRA:8V8 -43.90% 39 Marketable Securities is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:8V8 with a GF Score™ of 39/100 and a GF Value™ of €0.04. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Genetic Analysis AS's Marketable Securities for the quarter that ended in Mar. 2026 was €0.00 Mil.

Genetic Analysis AS  (FRA:8V8) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Genetic Analysis AS Marketable Securities Related Terms

Genetic Analysis AS Marketable Securities Historical Data

* Premium members only.

The historical data trend for Genetic Analysis AS's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Analysis AS Marketable Securities Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Genetic Analysis AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:8V8
39GF Score
Genetic Analysis AS FRA:8V8
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genetic Analysis AS Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
Genetic Analysis AS (FRA:8V8) has a Marketable Securities of €0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Genetic Analysis AS and its competitors.
Is Genetic Analysis AS's Marketable Securities too high?
Genetic Analysis AS's current Marketable Securities is €0.00 Mil. Overall, Genetic Analysis AS has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's Marketable Securities compare to TMO and DHR?
Genetic Analysis AS's Marketable Securities of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Diagnostics & Research company?
A good Marketable Securities depends on the Medical Diagnostics & Research industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Genetic Analysis AS and its competitors. Genetic Analysis AS's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Genetic Analysis AS (FRA:8V8) has a current Marketable Securities of €0.00 Mil. The stock's GF Value™ is €0.04, compared to a current price of €0.02 — trading 42.5% below its estimated fair value. The current Marketable Securities is €0.00 Mil. Genetic Analysis AS's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Genetic Analysis AS (FRA:8V8), the current Marketable Securities is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genetic Analysis AS (FRA:8V8) Overvalued in 2026?

Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be undervalued. The current stock price of €0.02 is trading 42.5% below its estimated GF Value™ of €0.04.

Key valuation signals for FRA:8V8:

  • Marketable Securities: €0.00 Mil
  • GF Value™: €0.04 vs. price of €0.02 (42.5% below fair value)
  • GF Score™: 39/100 with 3 warning signs

No single metric tells the full story. See the FRA:8V8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genetic Analysis AS Business Description

Other Exchanges GEAN:Sweden
Address Ulvenveien 80, Oslo, NOR, 0581
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
39GF Score

Get the complete analysis for FRA:8V8

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price
€0.04
GF Value